Aurobindo Pharma has released the transcript of its Q2 FY27 earnings conference call, held on November 5, 2026. The call detailed the company’s financial results for the second quarter and half-year ended September 30, 2026. Management discussed key achievements, including the acquisition of Lannett, revenue growth across segments like US and Europe, and provided an outlook for FY27 and FY28, highlighting strategic priorities and business expansion plans.
Aurobindo Pharma Q2 FY27 Earnings Call Transcript Released
Aurobindo Pharma Limited has disseminated the transcript of its Earnings Conference Call for the Second Quarter of FY27, which took place on November 5, 2026. This release provides a comprehensive overview of the company’s financial performance for the quarter and half-year ending September 30, 2026.
Key Financial Highlights and Strategic Initiatives
The call featured insights from senior management, including the CEO of Aurobindo Biosimilars, Vaccines and Peptide Businesses, Dr. Satakarni Makkapati, and the CFO, S. Subramanian. A major highlight discussed was the completion of the acquisition of Lannett, which is expected to bolster the company’s US presence and capabilities. Revenue performance was strong, with total revenue reaching ₹10,263 crore, a 24% year-on-year growth. Operating EBITDA stood at ₹2,156 crore, marking a 28% year-on-year increase with a margin of 21%. Formulation revenue grew by 24%, accounting for 89% of consolidated revenue, while API revenue saw a 21% year-on-year growth.
Geographical Performance and Segmental Contributions
The US market reported revenues of ₹4,555 crore (USD 477 million), reflecting a 25% year-on-year growth, driven by new product launches and an acceleration in complex and differentiated products. Europe delivered €288 million with constant currency growth of 18%. Growth markets contributed ₹1,026 crore (USD 107 million), a 16% year-on-year increase.
Outlook and Future Growth Drivers
Aurobindo Pharma reiterated its FY27 guidance, projecting double-digit revenue growth and EBITDA margins north of 21%, with an absolute EBITDA in excess of ₹8,000 crore. The company anticipates further expansion of EBITDA margins to upwards of 22% in FY28. Strategic priorities include strengthening the US business through Lannett integration, expanding the differentiated product portfolio in areas like respiratory therapy, and focusing on biosimilars and specialty products. The CDMO business is also being developed, leveraging acquired capabilities.
Operational Updates
The company mentioned the launch of ADQUEY, its first new chemical entity/NDA product for atopic dermatitis. Updates were also provided on the Raleigh unit’s VAI classification, the China oral solid dosage facility’s increasing importance, and the API and backward integration capabilities. Capital expenditure for the quarter was USD 89 million, allocated towards development capabilities and strategic priorities.
Guidance for FY28
Looking ahead to FY28, management expressed optimism, expecting a significantly better performance than FY27, driven by the full-year benefit of Lannett, advancements in China operations, and growth in biosimilars. The company anticipates the business tilt to move towards a 50:50 split between the US and the rest of the world by FY28-FY29.
Source: BSE
